Use of filters for removal of toxins in acute liver failure patients .

Use of HA 330-II for Hemofiltration in patients with ALF as a bridge to Liver Transplantation: Clinical Evaluation Protocol.

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/12/022536

Enrollment

Registered

2019-12-27

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K720- Acute and subacute hepatic failure

Interventions

Intervention1: HA 330-II Plus SMT: Hemoperfusion treatment with HA 330-II, one unit for 2-4 hours treatment, for 3 consecutive days along with SMT as per patients requirement. Control Intervention1: S

Eligibility

Inclusion criteria

Inclusion criteria: Acute Liver Failure patients with SIRS and Hepatic Encephalopathy, without hyperbilirubinemia.

Exclusion criteria

Exclusion criteria: 1. Patients with age less than 18 years or more than 65 years. 2. Extremely moribund patients with an expected life expectancy of less than 24 hours or with poor prognosis. 3. With poor blood clotting function and PTA 4. Active Bleed. 5. Chronic heart, lung or kidney disease. 6. Malignant tumors including liver cancer. 7. Past history of organ transplantation.

Design outcomes

Primary

Measure	Time frame
Liver transplantation-free survival during hospital stay.Timepoint: Day 3, 7	—

Secondary

Measure	Time frame
Improvement in APACHE-II score.Timepoint: Day 1, 2, 3, 7;Improvement in CLIF-SOFA score. Timepoint: Day 1, 2, 3, 7;Improvement in SIRS score.Timepoint: Day 1, 2, 3, 7;Improvement in SOFA score.Timepoint: Day 1, 2, 3, 7	—

Countries

India

Contacts

Public ContactDr Mithun Sharma

Asian Institute of Gastroenterology

drmithunsharma@gmail.com08790622655

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026